References:
1.Moosa ANV. Antiepileptic drug treatment of epilepsy in children. Continuum (Minneap Minn) 2019; 25 (2): 381‒407.
2.Nordli DR Jr, Bagiella E, Arzimanoglou A, et al. Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures. Neurology 2020; 94 (17): e1845‒e1852.
3.Pellock JM, Carman WJ, Thyagarajan V, et al. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012; 79 (14): 1482‒1489.
4.Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008; 5 (8): e166.
5.Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 2012; 9: CD001901.
6.Chen D, Bian H, Zhang L. A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy. Neuropsychiatr Dis Treat 2019; 15: 905‒917.
7.Xue-Ping W, Hai-Jiao W, Li-Na Z, et al. Risk factors for drug-resistant epilepsy: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (30): e16402.
8.Karaoğlu P, Yaş U, Polat Aİ, et al. Clinical predictors of drug-resistant epilepsy in children. Turk J Med Sci 2021; 51 (3): 1249‒1252.
9.Ayoub D, Jaafar F, Al-Hajje A, et al. Predictors of drug-resistant epilepsy in childhood epilepsy syndromes: A subgroup analysis from a prospective cohort study. Epilepsia 2024; 65 (10): 2995‒3009.
